Neutrophil Side Fluorescent Light (NEU-SFL) in COVID-19 Patients
NCT ID: NCT05413824
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2233 participants
OBSERVATIONAL
2022-06-02
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators propose to analyze the NEU-SFL parameter, obtained automatically on the Sysmex™ blood count machine (Sysmex Corporation, Kobe, Japan) and which is considered as a reflect of neutrophil extracellular traps formation, in these two groups of patients. The aim was to evaluate whether this parameter could be used to predict the risk of death related to COVID 19.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients
NCT04434157
Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management
NCT04668170
Identification of Novel Factors Leading to Activated Macrophage Expansion in COVID19 - INFLAME Study
NCT04903834
Association of the Neutrophil/Lymphocyte Ratio With Pulmonary Complications and Mortality in COVID-19 Patients
NCT05052346
Predictive Immune Biomarkers for COVID-19 Pathogenesis
NCT04385108
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 survivors
Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who survived.
No interventions assigned to this group
COVID-19 Deceased
Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who died.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anissa MEGZARI
Role: STUDY_CHAIR
CHU Nimes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Nimes
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fortier M, Chea M, Ain C, Loyens M, Boudemaghe T, Gris JC, Bouvier S. Direct blood fluorescence signal intensity of neutrophils (NEU-SFL): A predictive marker of death in hospitalized COVID-19 patients? Front Med (Lausanne). 2022 Dec 21;9:1062112. doi: 10.3389/fmed.2022.1062112. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Local/2022/SB-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.